0001209191-21-068582.txt : 20211208 0001209191-21-068582.hdr.sgml : 20211208 20211208180601 ACCESSION NUMBER: 0001209191-21-068582 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211207 FILED AS OF DATE: 20211208 DATE AS OF CHANGE: 20211208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCCLUNG BARBARA G CENTRAL INDEX KEY: 0001231321 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40631 FILM NUMBER: 211479766 MAIL ADDRESS: STREET 1: CARIBOU BIOCIENCES, INC. STREET 2: 2929 7TH STREET, SUITE 105 CITY: BERKELEY STATE: CA ZIP: 94710 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Caribou Biosciences, Inc. CENTRAL INDEX KEY: 0001619856 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 453728228 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2929 7TH STREET, SUITE 105 CITY: BERKELEY STATE: CA ZIP: 94710 BUSINESS PHONE: 510-982-6030 MAIL ADDRESS: STREET 1: 2929 7TH STREET, SUITE 105 CITY: BERKELEY STATE: CA ZIP: 94710 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-07 0 0001619856 Caribou Biosciences, Inc. CRBU 0001231321 MCCLUNG BARBARA G 2929 7TH STREET, SUITE 105 BERKELEY CA 94710 0 1 0 0 Chief Legal Officer Common Stock 2021-12-07 4 P 0 12 2.69 A 342856 D Common Stock 2021-12-07 4 P 0 6115 2.69 A 348971 D Option to purchase Common Stock 2.69 2021-12-07 4 X 0 12 0.00 D 2028-06-11 Common Stock 12 77 D Option to purchase Common Stock 2.69 2021-12-07 4 X 0 6115 0.00 D 2029-09-30 Common Stock 6115 74836 D These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on June 12, 2022, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on October 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. /s/ Rachel E. Haurwitz, as attorney-in-fact 2021-12-08